Liver Resection Versus Embolization for Recurrent Hepatocellular Carcinoma
Background Despite curative resection, hepatocellular carcinoma (HCC) has a high probability of recurrence. We validated the potential role of liver resection (LR) for recurrent HCC. Methods Patients with intrahepatic recurrence with up to three lesions were included. We compared survival times of p...
Gespeichert in:
| Veröffentlicht in: | World journal of surgery 2020-01, Vol.44 (1), p.232-240 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 240 |
|---|---|
| container_issue | 1 |
| container_start_page | 232 |
| container_title | World journal of surgery |
| container_volume | 44 |
| creator | Midorikawa, Yutaka Takayama, Tadatoshi Moriguchi, Masamichi Yagi, Rempei Yamagishi, Shunsuke Nakayama, Hisashi Aramaki, Osamu Yamazaki, Shintaro Tsuji, Shingo Higaki, Tokio |
| description | Background
Despite curative resection, hepatocellular carcinoma (HCC) has a high probability of recurrence. We validated the potential role of liver resection (LR) for recurrent HCC.
Methods
Patients with intrahepatic recurrence with up to three lesions were included. We compared survival times of patients undergoing their first LR to those of patients undergoing repeated LR. Then, survival times of the patients who had undergone LR and transcatheter chemoembolization (TACE) for recurrent HCC after propensity score matching were compared.
Results
After a median follow-up period of 3.1 years (range, 0.2–16.3), median overall survival times were 6.5 years (95% CI 6.0–7.0), 5.7 years (5.2–6.2), and 5.1 years (4.9–7.3) for the first LR (
n
= 1234), second LR (
n
= 273), and third LR (
n
= 90) groups, respectively. Severe complications frequently occurred in the first LR group (
p
= 0.059). Operative times were significantly longer for the third LR group (
p
= 0.012). After the first recurrence, median survival times after one-to-one pair matching were 5.7 years (95% CI 4.5–6.5) and 3.1 years (2.1–3.8) for the second LR group (
n
= 146) and TACE group (
n
= 146), respectively (
p
|
| doi_str_mv | 10.1007/s00268-019-05225-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2305031281</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2305031281</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4924-90a2f511fe1d4da571717e4ab867ba5ec41f5ce0d46c31258610999fd0e0dd413</originalsourceid><addsrcrecordid>eNqNkUtP3DAUhS1UBNNp_0AXKFI3bAL3-pUJuzKCAhqpEhS6tDzOTRWUxIM9oaK_Hg_hIbGoKi9sHX3n6OiYsS8IBwhQHEYArmc5YJmD4lzlfItNUAqec8HFBzYBoWV6o9hlH2O8BcBCg95huwI1KCxgwi4WzT2F7JIiuXXj--yGQhxidtItfdv8tU9a7TeEG0Kgfp2d0cquvaO2HVobsrkNrul9Zz-x7dq2kT4_31N2fXryc36WL358P59_W-ROllzmJVheK8SasJKVVQWmQ9IuZ7pYWkVOYq0cQSW1E8jVTCOUZVlXkLRKopiy_TF3FfzdQHFtuiZu6tie_BANF6AgOWcb9Os79NYPoU_tEsVLBMm1ThQfKRd8jIFqswpNZ8ODQTCbpc24tElLm6elk3vK9p6jh2VH1avlZdoEHI3An6alh_-INL8uro5Pk5y-cMrEaI7J1_-m8Fb8H50eAZ0-mOk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2329104266</pqid></control><display><type>article</type><title>Liver Resection Versus Embolization for Recurrent Hepatocellular Carcinoma</title><source>Wiley Online Library Journals Frontfile Complete</source><source>SpringerLink Journals - AutoHoldings</source><creator>Midorikawa, Yutaka ; Takayama, Tadatoshi ; Moriguchi, Masamichi ; Yagi, Rempei ; Yamagishi, Shunsuke ; Nakayama, Hisashi ; Aramaki, Osamu ; Yamazaki, Shintaro ; Tsuji, Shingo ; Higaki, Tokio</creator><creatorcontrib>Midorikawa, Yutaka ; Takayama, Tadatoshi ; Moriguchi, Masamichi ; Yagi, Rempei ; Yamagishi, Shunsuke ; Nakayama, Hisashi ; Aramaki, Osamu ; Yamazaki, Shintaro ; Tsuji, Shingo ; Higaki, Tokio</creatorcontrib><description>Background
Despite curative resection, hepatocellular carcinoma (HCC) has a high probability of recurrence. We validated the potential role of liver resection (LR) for recurrent HCC.
Methods
Patients with intrahepatic recurrence with up to three lesions were included. We compared survival times of patients undergoing their first LR to those of patients undergoing repeated LR. Then, survival times of the patients who had undergone LR and transcatheter chemoembolization (TACE) for recurrent HCC after propensity score matching were compared.
Results
After a median follow-up period of 3.1 years (range, 0.2–16.3), median overall survival times were 6.5 years (95% CI 6.0–7.0), 5.7 years (5.2–6.2), and 5.1 years (4.9–7.3) for the first LR (
n
= 1234), second LR (
n
= 273), and third LR (
n
= 90) groups, respectively. Severe complications frequently occurred in the first LR group (
p
= 0.059). Operative times were significantly longer for the third LR group (
p
= 0.012). After the first recurrence, median survival times after one-to-one pair matching were 5.7 years (95% CI 4.5–6.5) and 3.1 years (2.1–3.8) for the second LR group (
n
= 146) and TACE group (
n
= 146), respectively (
p
< 0.001). The median survival time of the third LR group (
n
= 41) (6.2 years; 95% CI 3.7–NA) was also longer than that of TACE group (
n
= 41) (3.4 years; 1.8–4.5;
p
= 0.010) after the second recurrence.
Conclusions
Repeated LR for recurrent HCC is the procedure of choice if there are three or fewer tumors.</description><identifier>ISSN: 0364-2313</identifier><identifier>EISSN: 1432-2323</identifier><identifier>DOI: 10.1007/s00268-019-05225-2</identifier><identifier>PMID: 31605170</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Abdominal Surgery ; Cardiac Surgery ; Complications ; Embolization ; General Surgery ; Hepatectomy ; Hepatocellular carcinoma ; Liver ; Liver cancer ; Matching ; Medicine ; Medicine & Public Health ; Original Scientific Report ; Surgery ; Survival ; Thoracic Surgery ; Tumors ; Vascular Surgery</subject><ispartof>World journal of surgery, 2020-01, Vol.44 (1), p.232-240</ispartof><rights>Société Internationale de Chirurgie 2019</rights><rights>2020 The Author(s) under exclusive licence to Société Internationale de Chirurgie</rights><rights>World Journal of Surgery is a copyright of Springer, (2019). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4924-90a2f511fe1d4da571717e4ab867ba5ec41f5ce0d46c31258610999fd0e0dd413</citedby><cites>FETCH-LOGICAL-c4924-90a2f511fe1d4da571717e4ab867ba5ec41f5ce0d46c31258610999fd0e0dd413</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00268-019-05225-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00268-019-05225-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,41464,42533,45550,45551,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31605170$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Midorikawa, Yutaka</creatorcontrib><creatorcontrib>Takayama, Tadatoshi</creatorcontrib><creatorcontrib>Moriguchi, Masamichi</creatorcontrib><creatorcontrib>Yagi, Rempei</creatorcontrib><creatorcontrib>Yamagishi, Shunsuke</creatorcontrib><creatorcontrib>Nakayama, Hisashi</creatorcontrib><creatorcontrib>Aramaki, Osamu</creatorcontrib><creatorcontrib>Yamazaki, Shintaro</creatorcontrib><creatorcontrib>Tsuji, Shingo</creatorcontrib><creatorcontrib>Higaki, Tokio</creatorcontrib><title>Liver Resection Versus Embolization for Recurrent Hepatocellular Carcinoma</title><title>World journal of surgery</title><addtitle>World J Surg</addtitle><addtitle>World J Surg</addtitle><description>Background
Despite curative resection, hepatocellular carcinoma (HCC) has a high probability of recurrence. We validated the potential role of liver resection (LR) for recurrent HCC.
Methods
Patients with intrahepatic recurrence with up to three lesions were included. We compared survival times of patients undergoing their first LR to those of patients undergoing repeated LR. Then, survival times of the patients who had undergone LR and transcatheter chemoembolization (TACE) for recurrent HCC after propensity score matching were compared.
Results
After a median follow-up period of 3.1 years (range, 0.2–16.3), median overall survival times were 6.5 years (95% CI 6.0–7.0), 5.7 years (5.2–6.2), and 5.1 years (4.9–7.3) for the first LR (
n
= 1234), second LR (
n
= 273), and third LR (
n
= 90) groups, respectively. Severe complications frequently occurred in the first LR group (
p
= 0.059). Operative times were significantly longer for the third LR group (
p
= 0.012). After the first recurrence, median survival times after one-to-one pair matching were 5.7 years (95% CI 4.5–6.5) and 3.1 years (2.1–3.8) for the second LR group (
n
= 146) and TACE group (
n
= 146), respectively (
p
< 0.001). The median survival time of the third LR group (
n
= 41) (6.2 years; 95% CI 3.7–NA) was also longer than that of TACE group (
n
= 41) (3.4 years; 1.8–4.5;
p
= 0.010) after the second recurrence.
Conclusions
Repeated LR for recurrent HCC is the procedure of choice if there are three or fewer tumors.</description><subject>Abdominal Surgery</subject><subject>Cardiac Surgery</subject><subject>Complications</subject><subject>Embolization</subject><subject>General Surgery</subject><subject>Hepatectomy</subject><subject>Hepatocellular carcinoma</subject><subject>Liver</subject><subject>Liver cancer</subject><subject>Matching</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Original Scientific Report</subject><subject>Surgery</subject><subject>Survival</subject><subject>Thoracic Surgery</subject><subject>Tumors</subject><subject>Vascular Surgery</subject><issn>0364-2313</issn><issn>1432-2323</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNqNkUtP3DAUhS1UBNNp_0AXKFI3bAL3-pUJuzKCAhqpEhS6tDzOTRWUxIM9oaK_Hg_hIbGoKi9sHX3n6OiYsS8IBwhQHEYArmc5YJmD4lzlfItNUAqec8HFBzYBoWV6o9hlH2O8BcBCg95huwI1KCxgwi4WzT2F7JIiuXXj--yGQhxidtItfdv8tU9a7TeEG0Kgfp2d0cquvaO2HVobsrkNrul9Zz-x7dq2kT4_31N2fXryc36WL358P59_W-ROllzmJVheK8SasJKVVQWmQ9IuZ7pYWkVOYq0cQSW1E8jVTCOUZVlXkLRKopiy_TF3FfzdQHFtuiZu6tie_BANF6AgOWcb9Os79NYPoU_tEsVLBMm1ThQfKRd8jIFqswpNZ8ODQTCbpc24tElLm6elk3vK9p6jh2VH1avlZdoEHI3An6alh_-INL8uro5Pk5y-cMrEaI7J1_-m8Fb8H50eAZ0-mOk</recordid><startdate>202001</startdate><enddate>202001</enddate><creator>Midorikawa, Yutaka</creator><creator>Takayama, Tadatoshi</creator><creator>Moriguchi, Masamichi</creator><creator>Yagi, Rempei</creator><creator>Yamagishi, Shunsuke</creator><creator>Nakayama, Hisashi</creator><creator>Aramaki, Osamu</creator><creator>Yamazaki, Shintaro</creator><creator>Tsuji, Shingo</creator><creator>Higaki, Tokio</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>202001</creationdate><title>Liver Resection Versus Embolization for Recurrent Hepatocellular Carcinoma</title><author>Midorikawa, Yutaka ; Takayama, Tadatoshi ; Moriguchi, Masamichi ; Yagi, Rempei ; Yamagishi, Shunsuke ; Nakayama, Hisashi ; Aramaki, Osamu ; Yamazaki, Shintaro ; Tsuji, Shingo ; Higaki, Tokio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4924-90a2f511fe1d4da571717e4ab867ba5ec41f5ce0d46c31258610999fd0e0dd413</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Abdominal Surgery</topic><topic>Cardiac Surgery</topic><topic>Complications</topic><topic>Embolization</topic><topic>General Surgery</topic><topic>Hepatectomy</topic><topic>Hepatocellular carcinoma</topic><topic>Liver</topic><topic>Liver cancer</topic><topic>Matching</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Original Scientific Report</topic><topic>Surgery</topic><topic>Survival</topic><topic>Thoracic Surgery</topic><topic>Tumors</topic><topic>Vascular Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Midorikawa, Yutaka</creatorcontrib><creatorcontrib>Takayama, Tadatoshi</creatorcontrib><creatorcontrib>Moriguchi, Masamichi</creatorcontrib><creatorcontrib>Yagi, Rempei</creatorcontrib><creatorcontrib>Yamagishi, Shunsuke</creatorcontrib><creatorcontrib>Nakayama, Hisashi</creatorcontrib><creatorcontrib>Aramaki, Osamu</creatorcontrib><creatorcontrib>Yamazaki, Shintaro</creatorcontrib><creatorcontrib>Tsuji, Shingo</creatorcontrib><creatorcontrib>Higaki, Tokio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>World journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Midorikawa, Yutaka</au><au>Takayama, Tadatoshi</au><au>Moriguchi, Masamichi</au><au>Yagi, Rempei</au><au>Yamagishi, Shunsuke</au><au>Nakayama, Hisashi</au><au>Aramaki, Osamu</au><au>Yamazaki, Shintaro</au><au>Tsuji, Shingo</au><au>Higaki, Tokio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Liver Resection Versus Embolization for Recurrent Hepatocellular Carcinoma</atitle><jtitle>World journal of surgery</jtitle><stitle>World J Surg</stitle><addtitle>World J Surg</addtitle><date>2020-01</date><risdate>2020</risdate><volume>44</volume><issue>1</issue><spage>232</spage><epage>240</epage><pages>232-240</pages><issn>0364-2313</issn><eissn>1432-2323</eissn><abstract>Background
Despite curative resection, hepatocellular carcinoma (HCC) has a high probability of recurrence. We validated the potential role of liver resection (LR) for recurrent HCC.
Methods
Patients with intrahepatic recurrence with up to three lesions were included. We compared survival times of patients undergoing their first LR to those of patients undergoing repeated LR. Then, survival times of the patients who had undergone LR and transcatheter chemoembolization (TACE) for recurrent HCC after propensity score matching were compared.
Results
After a median follow-up period of 3.1 years (range, 0.2–16.3), median overall survival times were 6.5 years (95% CI 6.0–7.0), 5.7 years (5.2–6.2), and 5.1 years (4.9–7.3) for the first LR (
n
= 1234), second LR (
n
= 273), and third LR (
n
= 90) groups, respectively. Severe complications frequently occurred in the first LR group (
p
= 0.059). Operative times were significantly longer for the third LR group (
p
= 0.012). After the first recurrence, median survival times after one-to-one pair matching were 5.7 years (95% CI 4.5–6.5) and 3.1 years (2.1–3.8) for the second LR group (
n
= 146) and TACE group (
n
= 146), respectively (
p
< 0.001). The median survival time of the third LR group (
n
= 41) (6.2 years; 95% CI 3.7–NA) was also longer than that of TACE group (
n
= 41) (3.4 years; 1.8–4.5;
p
= 0.010) after the second recurrence.
Conclusions
Repeated LR for recurrent HCC is the procedure of choice if there are three or fewer tumors.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>31605170</pmid><doi>10.1007/s00268-019-05225-2</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0364-2313 |
| ispartof | World journal of surgery, 2020-01, Vol.44 (1), p.232-240 |
| issn | 0364-2313 1432-2323 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2305031281 |
| source | Wiley Online Library Journals Frontfile Complete; SpringerLink Journals - AutoHoldings |
| subjects | Abdominal Surgery Cardiac Surgery Complications Embolization General Surgery Hepatectomy Hepatocellular carcinoma Liver Liver cancer Matching Medicine Medicine & Public Health Original Scientific Report Surgery Survival Thoracic Surgery Tumors Vascular Surgery |
| title | Liver Resection Versus Embolization for Recurrent Hepatocellular Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T21%3A35%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Liver%20Resection%20Versus%20Embolization%20for%20Recurrent%20Hepatocellular%20Carcinoma&rft.jtitle=World%20journal%20of%20surgery&rft.au=Midorikawa,%20Yutaka&rft.date=2020-01&rft.volume=44&rft.issue=1&rft.spage=232&rft.epage=240&rft.pages=232-240&rft.issn=0364-2313&rft.eissn=1432-2323&rft_id=info:doi/10.1007/s00268-019-05225-2&rft_dat=%3Cproquest_cross%3E2305031281%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2329104266&rft_id=info:pmid/31605170&rfr_iscdi=true |